CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 143 enrolled
Drug / intervention
Omega-3 Fatty Acid +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01027143
NCT01027143Phase 3Completed
CompareCT.gov

Obesity & Asthma: Nutrigenetic Response to Omega-3 Fatty Acids

Nemours Children's Clinic·interventional·Posted Dec 7, 2009·Updated Sep 8, 2023

In Brief

A Phase 3 clinical trial evaluating omega-3 polyunsaturated fatty acids and Omega-3 Fatty Acid for Asthma and Obesity. Completed, enrolled 143 participants across 3 sites.

Detailed Summary

This project will assess the effectiveness of omega-3 fatty acid supplementation in controlling asthma symptoms among obese asthmatics, and will assess if a person's genes influence response to treatment (personalized medicine). This project may improve our ability to treat asthma and our understanding of the link between obesity and asthma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma, Obesity
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI), Office of Dietary Supplements (ODS)

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 7, 2009
Enrollment StartJul 1, 2010
Primary CompletionOct 22, 2016
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 16.6 years ago

Interventions

omega-3 polyunsaturated fatty acidsdietary

ProEPA Xtra 1000mg softgels: 3 softgels twice daily

Omega-3 Fatty Aciddrug

Soybean oil: 3(age 12-25) matched softgel caps twice daily